Whitehawk Therapeutics (WHWK) Interest & Investment Income (2016 - 2026)
Whitehawk Therapeutics (WHWK) reported Interest & Investment Income of $1.3 million for Q1 2026, up 67.89% year-over-year from $791000.0 in Q1 2025, and down 17.57% on a QoQ basis from $1.6 million in Q4 2025.
Whitehawk Therapeutics (WHWK) has 11 years of Interest & Investment Income data on file, last reported at $1.3 million in Q1 2026.
- Quarterly Interest & Investment Income rose 67.89% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.8 million (up 97.09% YoY) and the FY2025 annual result came in at $6.2 million, up 58.75% from the prior year.
- Interest & Investment Income slipped to $1.3 million in Q1 2026 per WHWK's latest filing, from $1.6 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at $2.0 million in Q2 2025 and bottomed at $15000.0 in Q1 2022.
- The 5-year median for Interest & Investment Income is $1.3 million (2026), against an average of $1.2 million.
- The widest annual swing landed in 2022, when Interest & Investment Income jumped 15700.0%; it then tumbled 54.93% in 2024.
- Tracing WHWK's Interest & Investment Income over 5 years: stood at $1.6 million in 2022, then decreased by 6.66% to $1.5 million in 2023, then plunged by 54.93% to $676000.0 in 2024, then soared by 138.31% to $1.6 million in 2025, then dropped by 17.57% to $1.3 million in 2026.
- Per Business Quant, the three latest WHWK Interest & Investment Income figures stand at $1.3 million (Q1 2026), $1.6 million (Q4 2025), and $1.8 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 7.90 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 114.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 305,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 26.60 Mn |
| 10 | Whitehawk Therapeutics | 312.26 Mn | 189.22 Mn | - | 1.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.33 Mn |
| Dec 31, 2025 | 1.61 Mn |
| Sep 30, 2025 | 1.85 Mn |
| Jun 30, 2025 | 1.98 Mn |
| Mar 31, 2025 | 791,000.00 |
| Dec 31, 2024 | 676,000.00 |
| Sep 30, 2024 | 906,000.00 |
| Jun 30, 2024 | 1.06 Mn |
| Mar 31, 2024 | 1.28 Mn |
| Dec 31, 2023 | 1.50 Mn |
| Sep 30, 2023 | 1.61 Mn |
| Jun 30, 2023 | 1.64 Mn |
| Mar 31, 2023 | 1.66 Mn |
| Dec 31, 2022 | 1.61 Mn |
| Sep 30, 2022 | 620,000.00 |
| Jun 30, 2022 | 158,000.00 |
| Mar 31, 2022 | 15,000.00 |
| Dec 31, 2021 | 12,000.00 |
| Jun 30, 2021 | 1,000.00 |
| Mar 31, 2021 | 3,036.00 |
| Sep 30, 2020 | 1,000.00 |
| Jun 30, 2020 | 20,119.00 |
| Mar 31, 2020 | 116,370.00 |
| Dec 31, 2019 | 167,935.00 |
| Sep 30, 2019 | 239,405.00 |
| Jun 30, 2019 | 290,379.00 |
| Mar 31, 2019 | 333,120.00 |
| Dec 31, 2018 | 347,589.00 |
| Sep 30, 2018 | 333,047.00 |
| Jun 30, 2018 | 46,464.00 |
| Mar 31, 2018 | 51,116.00 |
| Dec 31, 2017 | 53,830.00 |
| Sep 30, 2017 | 59,847.00 |
| Jun 30, 2017 | 52,316.00 |
| Mar 31, 2017 | -271,775.00 |
| Dec 31, 2016 | -227,652.00 |
| Sep 30, 2016 | -166,847.00 |
| Jun 30, 2016 | -88,783.00 |
| Mar 31, 2016 | 1,078.00 |